Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.
OBJECTIVE
To investigate the effects of chimeric CD4 monoclonal antibody cM-T412 treatment in patients with rheumatoid arthritis (RA).


METHODS
Thirty-two RA patients received daily doses of 10, 50, or 100 mg of cM-T412 intravenously for 7 days.


RESULTS
There was a sustained decrease in the number of CD4+ T lymphocytes in all patients. Those who received 50 mg and 100 mg of the antibody experienced significant reductions in disease activity.


CONCLUSIONS
Treatment with cM-T412 appears to have a dose-dependent beneficial effect in RA patients. The clinical effects of cM-T412 are independent of the depressed numbers of circulating CD4+ T cells.
van der Lubbe
P A
PA
Department of Rheumatology, University Hospital Leiden, The Netherlands.
Reiter
C
C
Breedveld
F C
FC
Krüger
K
K
Schattenkirchner
M
M
Sanders
M E
ME
Riethmüller
G
G
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000503:physiopathology / Q000628:therapy*; D015704:CD4 Antigens / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D011993:Recombinant Fusion Proteins